Rainer-Georg Goeldner

3.6k total citations · 1 hit paper
15 papers, 1.8k citations indexed

About

Rainer-Georg Goeldner is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, Rainer-Georg Goeldner has authored 15 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 3 papers in Genetics. Recurrent topics in Rainer-Georg Goeldner's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (6 papers), HER2/EGFR in Cancer Research (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Rainer-Georg Goeldner is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (6 papers), HER2/EGFR in Cancer Research (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Rainer-Georg Goeldner collaborates with scholars based in Germany, United States and United Kingdom. Rainer-Georg Goeldner's co-authors include Kevin K. Brown, Rozsa Schlenker‐Herceg, Vincent Cottin, Simon Walsh, Athol U. Wells, Kay Tetzlaff, Emmanuelle Clerisme-Beaty, Kevin R. Flaherty, Anand Devaraj and Yoshikazu Inoue and has published in prestigious journals such as New England Journal of Medicine, Cancer Research and The Lancet Oncology.

In The Last Decade

Rainer-Georg Goeldner

14 papers receiving 1.8k citations

Hit Papers

Nintedanib in Progressive Fibrosing Interstitial Lung Dis... 2019 2026 2021 2023 2019 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
    2019 1.3k citations Kevin R. Flaherty, Athol U. Wells et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rainer-Georg Goeldner Germany 9 1.6k 631 409 275 237 15 1.8k
Danielle Antin‐Ozerkis United States 13 659 0.4× 191 0.3× 179 0.4× 81 0.3× 148 0.6× 28 1.2k
Kazushige Wakuda Japan 24 1.0k 0.7× 223 0.4× 47 0.1× 224 0.8× 1.1k 4.4× 117 1.6k
Hubert de Crémoux France 19 806 0.5× 176 0.3× 46 0.1× 204 0.7× 410 1.7× 48 1.2k
Sylvie Labrune France 13 434 0.3× 261 0.4× 39 0.1× 54 0.2× 469 2.0× 32 912
Giovanna Graziadei Italy 20 140 0.1× 302 0.5× 69 0.2× 95 0.3× 101 0.4× 82 1.2k
Tetsuhiko Taira Japan 20 636 0.4× 126 0.2× 47 0.1× 126 0.5× 589 2.5× 58 1.1k
Shogo Kumagai Japan 15 389 0.2× 63 0.1× 123 0.3× 177 0.6× 450 1.9× 37 1.0k
Zbyněk Bortlíček Czechia 18 482 0.3× 50 0.1× 170 0.4× 63 0.2× 513 2.2× 81 927
Alejandra Flores-Chávez Spain 9 230 0.1× 91 0.1× 75 0.2× 116 0.4× 730 3.1× 18 1.2k
Kakuhiro Yamaguchi Japan 15 470 0.3× 101 0.2× 36 0.1× 84 0.3× 222 0.9× 93 751

Countries citing papers authored by Rainer-Georg Goeldner

Since Specialization
Citations

This map shows the geographic impact of Rainer-Georg Goeldner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rainer-Georg Goeldner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rainer-Georg Goeldner more than expected).

Fields of papers citing papers by Rainer-Georg Goeldner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rainer-Georg Goeldner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rainer-Georg Goeldner. The network helps show where Rainer-Georg Goeldner may publish in the future.

Co-authorship network of co-authors of Rainer-Georg Goeldner

This figure shows the co-authorship network connecting the top 25 collaborators of Rainer-Georg Goeldner. A scholar is included among the top collaborators of Rainer-Georg Goeldner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rainer-Georg Goeldner. Rainer-Georg Goeldner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Scholz, Andreas, et al.. (2024). Safety, tolerability and pharmacokinetics of the phosphodiesterase 2 inhibitor BI 474121: An overview of phase I randomized trials in healthy volunteers. Journal of Psychopharmacology. 38(9). 807–817. 1 indexed citations
2.
Flaherty, Kevin R., Athol U. Wells, Vincent Cottin, et al.. (2021). Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. European Respiratory Journal. 59(3). 2004538–2004538. 65 indexed citations
3.
4.
Maher, Toby M., Kevin K. Brown, Michael Kreuter, et al.. (2021). Effects of nintedanib by inclusion criteria for progression of interstitial lung disease. European Respiratory Journal. 59(2). 2004587–2004587. 17 indexed citations
5.
Brown, Kevin K., Fernando J. Martínez, Simon Walsh, et al.. (2020). The natural history of progressive fibrosing interstitial lung diseases. European Respiratory Journal. 55(6). 2000085–2000085. 166 indexed citations
6.
Flaherty, Kevin R., Athol U. Wells, Vincent Cottin, et al.. (2020). Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial. 4578–4578. 1 indexed citations
7.
Flaherty, Kevin R., Athol U. Wells, Vincent Cottin, et al.. (2019). Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. New England Journal of Medicine. 381(18). 1718–1727. 1333 indexed citations breakdown →
8.
Flaherty, Kevin R., Athol U. Wells, Vincent Cottin, et al.. (2019). Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial. RCT1881–RCT1881. 4 indexed citations
9.
Martin, Nicolas, Nicolás Isambert, Carlos Gomez‐Roca, et al.. (2018). Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer. Cancer Chemotherapy and Pharmacology. 82(6). 979–986. 12 indexed citations
10.
11.
12.
Schnell, David, Holger Fuchs, Dietmar Ganßer, et al.. (2014). Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment. Cancer Chemotherapy and Pharmacology. 74(2). 267–275. 32 indexed citations
13.
Dittrich, Christian, Michael Fridrik, Robert A. Koenigsberg, et al.. (2014). A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors. Investigational New Drugs. 33(2). 409–422. 16 indexed citations
14.
Wind, Sven, et al.. (2013). Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients with Advanced Solid Tumours. Clinical Pharmacokinetics. 52(12). 1101–1109. 76 indexed citations
15.
Aftimos, Philippe, Herlinde Dumez, Ahmad Awada, et al.. (2013). Abstract B281: Phase I study of two dosing schedules of BI 847325, an orally administered dual inhibitor of MEK and aurora kinase B, in patients with advanced solid tumors.. Molecular Cancer Therapeutics. 12(11_Supplement). B281–B281. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Danielle Antin‐Ozerkis Breakdown of academic impact, for papers by Kazushige Wakuda Breakdown of academic impact, for papers by Hubert de Crémoux Breakdown of academic impact, for papers by Sylvie Labrune Breakdown of academic impact, for papers by Giovanna Graziadei Breakdown of academic impact, for papers by Tetsuhiko Taira Breakdown of academic impact, for papers by Shogo Kumagai Breakdown of academic impact, for papers by Zbyněk Bortlíček Breakdown of academic impact, for papers by Alejandra Flores-Chávez Breakdown of academic impact, for papers by Kakuhiro Yamaguchi
Rankless by CCL
2026